All articles tagged with #hong kong ipo
Shein is set to list on the Hong Kong Stock Exchange on October 13, 2026, at a valuation of approximately $26 billion. This represents a 70% drop from its 2022 peak of $98.2 billion. The company seeks to raise $1.7 billion but faces significant headwinds, including a $99 million first-quarter loss, the removal of US and EU tariff exemptions, and intense competition from rival Temu.
Shein posted a net loss of $99 million for the latest quarter ahead of its planned Hong Kong IPO, with profit margins narrowing to 4.9% in 2025 from 8.7% in 2024, as higher US/EU duties weigh on costs and demand. The firm says it may lift US prices to offset duties, and its US revenue share has fallen from 30% of sales in 2023 to 22% this year. While expanding into new markets, it faces EU probes into illegal products and ongoing supply-chain scrutiny, remains heavily reliant on Chinese factories, and is exploring diversification to Turkey ahead of listing.
Shanghai Biren Technology's shares more than doubled on their Hong Kong debut, raising HK$5.58 billion, amid a wave of AI and chip offerings in China driven by government support and efforts to reduce reliance on U.S. technology exports.
Baidu's AI chip unit Kunlunxin has confidentially filed for a Hong Kong IPO, aiming for a spin-off and separate listing, as part of China's broader push to develop domestic semiconductor alternatives amid U.S. export restrictions. The company, valued at around $3 billion, will remain a subsidiary of Baidu after the IPO, with details yet to be finalized.
Gold prices hit $4,000 for the first time amid global economic uncertainty driven by the U.S. government shutdown and political events in France, reflecting increased safe-haven demand. Meanwhile, stock markets showed mixed results, with Hong Kong's IPO market booming and U.S. markets declining due to concerns over AI profitability and government shutdown impacts.
Ab&B Bio-Tech's IPO in Hong Kong saw its stock soar over 169% on debut, driven by strong retail investor demand for its influenza vaccine and other health products, marking a successful entry amid a rally in healthcare stocks.